Page 2 - Variation Biotechnologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Globe and Mail
Bookmark
Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file .
This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
As COVID-19 was beginning its deadly trek around the globe last year, scientists at biopharmaceutical company VBI Vaccines were asking themselves a key question: Can a vaccine be created to deal with more than one kind of coronavirus?
The company, which is headquartered in Cambridge, Mass., and has its research operations in Ottawa, then began to develop a vaccine that would work against COVID-19 – in addition to SARS and MERS, the previous two coronavirus outbreaks, which began in 2002 and 2012 respectively. Last August, VBI’s Ottawa-based subsidiary, Variation Biotechnologies Inc., received a $56-million funding boost from the federal government to advance its program. ....

United Kingdom , Brian Ward , Jeff Baxter , Dennis Burton , Arinjay Banerjee , Eric Topol , Scripps Research Translational Institute In La Jolla , Variation Biotechnologies Inc , Mcgill University , University Of Saskatchewan , Adagio Therapeutics , Scripps Research Translational Institute , Covid 19 Vaccine , Coronavirus Vaccine , Vbi Vaccines , Variation Biotechnologies , Vido Intervac , Multivalent Vaccine , ஒன்றுபட்டது கிஂக்டம் , பிரையன் வார்டு , ஜெஃப் பாக்ஸ்டர் , டென்னிஸ் பர்டன் , அரிஞ்சய பானர்ஜி , எரிக் தோப்போல் , ஸ்கிரிப்ட்கள் ஆராய்ச்சி மொழிபெயர்ப்பு நிறுவனம் இல் லா ஜொல்லா , மகில் பல்கலைக்கழகம் ,